Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients. Read more on ATAI stock update.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Navy veteran Michael Giardina told Anderson Cooper he was able to "let go" of trauma from his childhood during a psychedelic ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Sarah Napthali lowers her voice over lunch when our conversation veers to the names of the drugs she used: LSD, MDMA, ...

like psilocybin and 5-MeO- DMT. 60 Minutes documented the psychedelic retreat last March, interviewing and filming a group of veterans before, during and afterwards. To qualify, the veterans ...

Now 29, Turner remembers the perspective that came to her in the months after she was crushed by that tree in Portland’s ...